Problems associated with switch to
modafinil - a novel alerting agent in narcolepsy
Guilleminault C, Aftab FA, Karadeniz D,
Philip P, Leger D
Stanford Sleep Disorders Clinic
and Research Center, CA 94605, USA.
c.guil@leland.stanford.edu
Eur J Neurol 2000 Jul; 7(4):381-4
ABSTRACT
Modafinil is a novel medication recently
approved for the treatment of narcolepsy and idiopathic hypersomnia.
Commonly, patients had already been prescribed medications for their
syndrome. This report outlines difficulties encountered in the
clinical practice of switching patients to modafinil. Naive subjects
accepted modafinil best. Subjects withdrawn from amphetamine had the
most problems and failure to withdraw. Venlafaxine hydrochloride
combined well with modafinil to control cataplectic attacks. Usage of
a progressive withdrawal protocol may ease the difficulties observed.
1. Modafinil for
sustaining the alertness of helicopter pilots
2. Modafinil augmentation
of antidepressant treatment
3. Modafinil the
unique properties of a new stimulant
4. Modafinil children
with attention-deficit/hyperactivity disorder
5. Modafinil dosage
and safety
6. Modafinil successful
treatment of hypersomnia & narcolepsy
7. Modafinil narcolepsy:
symptoms and management
8. Modafinil
amplification of cortical serotonin release
9. Modafinil
treatment of alcoholic organic brain syndrome
10. Modafinil
effect on melatonin, cortisol, and growth hormone
11. Modafinil
in obstructive sleep apnea-hypopnea syndrome
12. Modafinil
vs dextroamphetamine in treatment of adult ADHD
13. Modafinil
efficacy in narcolepsy
14. Modafinil
switching from narcolepsy drugs to modafinil
15. Modafinil
dopaminergic transmission mediates CNS stimulants
